Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
98.05
-1.47 (-1.48%)
At close: Dec 20, 2024, 4:03 PM
98.99
+0.94 (0.96%)
After-hours: Dec 20, 2024, 7:59 PM EST
Merck & Co. Employees
Merck & Co. had 72,000 employees as of December 31, 2023. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
$877,417
Profits / Employee
$168,722
Market Cap
248.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Novo Nordisk | 64,319 |
AbbVie | 50,000 |
MRK News
- 1 day ago - Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
- 2 days ago - Stock Of The Day: Where Does The Merck Downtrend End? - Benzinga
- 2 days ago - Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
- 2 days ago - Merck's HIV treatment meets main goal of two late-stage studies - Reuters
- 2 days ago - Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
- 3 days ago - Merck's weight-loss pill deal: what it means for Eli Lilly - Invezz
- 3 days ago - Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs. - Barrons
- 3 days ago - Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal - CNBC